Medical Condition News

RSS

HDAC inhibitors may be used to fight against skin cancers

In a study published in the journal Developmental Cell, Sarah Millar PhD, professor of Dermatology and Cell & Developmental Biology at the University of Pennsylvania School of Medicine, and colleagues demonstrate that a pair of enzymes called HDACs are critical to the proper formation of mammalian skin.

7 Dec 2010

New analysis of Soliris in patients with PNH presented at ASH Annual Meeting

Independent investigators reported today that patients with paroxysmal nocturnal hemoglobinuria who were treated long-term with Soliris (eculizumab) achieved survival comparable to that of an age- and gender-matched normal population. Findings from this investigator-led analysis were reported in an oral presentation today at the 52nd American Society of Hematology Annual Meeting and Exposition in Orlando.

7 Dec 2010

Outdoor exercise and physical activity increase risk of heat-related injuries

Outdoor exercise and physical activity increase the risk for heat-related injuries, including dangerous heat stroke. A new study finds that heat-injury rates are on the rise for all age groups, and football-playing boys are among the most vulnerable.

7 Dec 2010

Studies shows that social stress accelerates atherosclerosis development

Studies on genetically engineered mice show that social stress activates the immune system and accelerates the development of atherosclerosis. Commonly used drugs to reduce blood pressure, however, may stop this process. This is the conclusion of a thesis presented at the University of Gothenburg, Sweden.

7 Dec 2010

New analysis evaluates association between hemolysis, mortality in patients with PNH

Alexion Pharmaceuticals, Inc. today announced the presentation of an analysis from the National Data Registry in South Korea that evaluated the association between hemolysis and mortality in patients with paroxysmal nocturnal hemoglobinuria.

7 Dec 2010

FDA accepts for review Bristol-Myers Squibb's ORENCIA sBLA for severe RA

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for the subcutaneous formulation of ORENCIA® (abatacept), a treatment for adult patients with moderate to severe rheumatoid arthritis (RA) administered through an injection into the skin. Bristol-Myers Squibb submitted the sBLA to the FDA for the subcutaneous formulation of ORENCIA and received confirmation of its receipt on October 4, 2010.

7 Dec 2010

Researchers develop new drugs to prevent post-traumatic stress syndrome

Post-traumatic stress syndrome - when a severely stressful event triggers exaggerated and chronic fear - affects nearly 8 million people in the United States and is hard to treat. In a preclinical study, Northwestern Medicine scientists have for the first time identified the molecular cause of the debilitating condition and prevented it from occurring by injecting calming drugs into the brain within five hours of a traumatic event.

7 Dec 2010

Patients with rheumatoid arthritis face high risk of heart attack

The risk of having a heart attack is 60 per cent higher just a year after a patient has been diagnosed with rheumatoid arthritis, according to research published in the December issue of the Journal of Internal Medicine.

7 Dec 2010

No evidence of toxicity in hemophilia B patients enrolled in gene therapy trial

Investigators report no evidence of toxicity in the four hemophilia B patients enrolled to date in a gene therapy trial using a vector under development at St. Jude Children's Research Hospital and UCL (University College London) to correct the inherited bleeding disorder.

7 Dec 2010

ArQule initiates enrollment in ARQ 736 Phase 1 clinical trial for advanced solid tumors

ArQule, Inc. today announced the commencement of patient dosing in a Phase 1 clinical trial with ARQ 736, a small molecule inhibitor of the RAF kinases.

7 Dec 2010

New tool for predicting disease course in children with Crohn's disease

A new study published in the journal Inflammatory Bowel Diseases develops a computer based visual tool that can be used in “real time” to show pediatric Crohn’s disease (CD) patients’ predicted disease course and how this might be influenced by different treatment options.

6 Dec 2010

Preclinical data of ZIO-101 in various lymphoma models presented at ASH 2010

ZIOPHARM Oncology, Inc. announced today that new preclinical data on the novel mechanism of its organic arsenic darinaparsin (ZIO-101) in various lymphoma models were presented at the 52nd Annual Meeting and Exposition of the American Society of Hematology in Orlando Florida.

6 Dec 2010

New, HIV-like retroviruses linked to CFS, prostate cancer detected in healthy blood donors

In an unprecedented move, chronic fatigue syndrome patients published a half-page ad in The Washington Post today. The ad brings attention to new, HIV-like retroviruses, including XMRV, which have been linked to CFS and aggressive prostate cancer, and have been detected in healthy blood donors.

6 Dec 2010

Alexithymia associated with insecure attachment styles, emotional trauma: Research

Alexithymia is inversely related to mentalization and is associated with insecure attachment styles and emotional trauma, which influence the capacity to regulate affects induced by stressful events. Alexithymia and intrapsychic conflicts may both contribute to the pathogenesis of panic attacks.

6 Dec 2010

Performance of Myconostica's MycAssay Aspergillus in CF reported at British Thoracic Society meeting

At the prestigious annual British Thoracic Society meeting in London on December 1st, Dr Caroline Baxter reported the highly sensitive performance of Myconostica's real-time PCR assay MycAssayTM Aspergillus in cystic fibrosis sputum which is 260% more sensitive than the currently used culture.

6 Dec 2010

$Allos Therapeutics reports new analysis of PROPEL trial data of FOLOTYN in patients with refractory PTCL$

Allos Therapeutics reports new analysis of PROPEL trial data of FOLOTYN in patients with refractory PTCL

Allos Therapeutics, Inc. today reported new analysis of data from the Company's pivotal PROPEL trial of FOLOTYN (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma at the 52nd American Society of Hematology Annual Meeting in Orlando, Florida.

6 Dec 2010

Risk of heart attack increases soon after RA diagnosis: Research

6 Dec 2010

Telik announces positive results from Phase 2 trial of ezatiostat in patients with MDS

Telik, Inc. today announced positive results from a Phase 2 multicenter trial of oral ezatiostat hydrochloride (TELINTRA, TLK199) in patients with an International Prognostic System Score of low to intermediate-1 risk myelodysplastic syndrome.

6 Dec 2010

$Updated Phase 1 study data of ponatinib in patients with refractory CML, Ph+ ALL presented at ASH$

Updated Phase 1 study data of ponatinib in patients with refractory CML, Ph+ ALL presented at ASH

ARIAD Pharmaceuticals, Inc. today announced updated clinical data from a fully enrolled and ongoing Phase 1 study of its investigational pan-BCR-ABL inhibitor, ponatinib, in patients with resistant and refractory chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia.

6 Dec 2010

Study confirms importance of EEG as diagnostic tool in ICU

Bleeding in and around the brain (cerebral hemorrhage, including intra-cerebral hemorrhage, subdural hematoma, subarachnoid hemorrhage among other forms), from whatever cause (stroke, ruptured aneurysm, stroke, tumor, trauma, etc) can be very irritating to the electrical cells of the brain and affect how these cells transmit signals. If cells become very irritated and/or hyperactive, seizures can occur.

6 Dec 2010

Medical Condition News

HDAC inhibitors may be used to fight against skin cancers

New analysis of Soliris in patients with PNH presented at ASH Annual Meeting

Outdoor exercise and physical activity increase risk of heat-related injuries

Studies shows that social stress accelerates atherosclerosis development

New analysis evaluates association between hemolysis, mortality in patients with PNH

FDA accepts for review Bristol-Myers Squibb's ORENCIA sBLA for severe RA

Researchers develop new drugs to prevent post-traumatic stress syndrome

Patients with rheumatoid arthritis face high risk of heart attack

No evidence of toxicity in hemophilia B patients enrolled in gene therapy trial

ArQule initiates enrollment in ARQ 736 Phase 1 clinical trial for advanced solid tumors

New tool for predicting disease course in children with Crohn's disease

Preclinical data of ZIO-101 in various lymphoma models presented at ASH 2010

New, HIV-like retroviruses linked to CFS, prostate cancer detected in healthy blood donors

Alexithymia associated with insecure attachment styles, emotional trauma: Research

Performance of Myconostica's MycAssay Aspergillus in CF reported at British Thoracic Society meeting

Allos Therapeutics reports new analysis of PROPEL trial data of FOLOTYN in patients with refractory PTCL

Risk of heart attack increases soon after RA diagnosis: Research

Telik announces positive results from Phase 2 trial of ezatiostat in patients with MDS

Updated Phase 1 study data of ponatinib in patients with refractory CML, Ph+ ALL presented at ASH

Study confirms importance of EEG as diagnostic tool in ICU

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News